Celgene Corp

CELG-Q

NASDAQ:CELG

108.24
0.00 (0.00%)
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey.
More at Wikipedia

Analysis and Opinions about CELG-Q

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
January 17, 2020

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
January 17, 2020

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

SELL
SELL
November 27, 2019
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
November 27, 2019
He sold out because it's going to be merged with Bristol Myers, they received full value, and there's always deal risk. Celgene owners may get a premium if 3 drugs come to market and exceeded certain thresholds. This is a side bet, and not the way he likes to invest.
PAST TOP PICK
PAST TOP PICK
October 16, 2019

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 16, 2019

(A Top Pick Oct 22/18, Up 25%) The Bristol acquisition was perfect. CELG boasts strong competitive barriers to their products and their product pipeline will pleasantly surprise the market. He's not worried about the US election and the negative effect on US healthcare; in fact, he loves buying stocks when others fear or hate them.

COMMENT
COMMENT
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 25, 2019

He started buying BMY-N ahead of the merger discussions with CELG-Q. If the merger fails, holding the buyer is safer as arbitragers unwind hedges. The combined company would be a good cash flow generator, which would help internal growth and debt pay down.

DON'T BUY
DON'T BUY
August 6, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
August 6, 2019

Heading into the election cycle, pharma will be under pressure. He prefers being into medical devices. He has a hard time being excited about either CELG or BMY, especially if the market is currently jittery. (Analysts’ price target is $100.33)

PAST TOP PICK
PAST TOP PICK
May 3, 2019
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
Show full opinionHide full opinion
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
BUY
BUY
April 22, 2019
Bistol-Myers bought it which is good news for Celgene holders.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 22, 2019
Bistol-Myers bought it which is good news for Celgene holders.
PAST TOP PICK
PAST TOP PICK
April 8, 2019
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 8, 2019
(A Top Pick May 30/18, Up 22%) They have a lot of new products in their patent portfolio. They are being acquired. It would be a nice speculative holding in the marketplace when it closes.
PAST TOP PICK
PAST TOP PICK
February 11, 2019
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
February 11, 2019
(A Top Pick Mar 20/18, Down 0.2%) It was one of his hopes in the medical area for great growth. They are being acquired. He is going to keep holding it.
SELL
SELL
January 10, 2019
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
January 10, 2019
Having issues in terms of competition. They wanted to merge with Bristol. She doesn't think the combination makes it a better company. She would sell on the announcement (as the stock lifted).
BUY
BUY
December 31, 2018
It has a better growth pipeline. Biotech in the US is probably one of the better areas of growth. He prefers the IBB-Q ETF. He likes the sector. There is good growth potential.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
December 31, 2018
It has a better growth pipeline. Biotech in the US is probably one of the better areas of growth. He prefers the IBB-Q ETF. He likes the sector. There is good growth potential.
TOP PICK
TOP PICK
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
December 3, 2018
They're in oncology, particularly blood cancer. They've had some headwinds in some FDA submissions due to mistakes by management. So, the stock got punished. It's trading at 6.5x and generating a ton of cash flow as good test results come in. They are diversifying as they acquire. Hoeps investor sentiment improves. (Analysts’ price target is $108.61)
DON'T BUY
DON'T BUY
November 12, 2018
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
Show full opinionHide full opinion
Celgene Corp (CELG-Q)
November 12, 2018
They have drugs going off patent in 2020. They have 5 big names coming into trials at the same time. He is not clear on what will cause it to bounce. Don't buy lows. The price is confirmed by relative strength.
TOP PICK
TOP PICK
October 22, 2018

(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 22, 2018

(no dividend yield, Analysts' price target: not given) A global biotech focussed on cancer. They've stumbled recently, but phase 3 trials have been positive. Their drugs have a diminished chance of going generic, according to data. Attractive value. smart managers and a rich pipeline of drugs coming.

DON'T BUY
DON'T BUY
October 10, 2018

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
October 10, 2018

They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to battle through. He would suggest taking a loss if you hold this one, because the future capex requirements will be more expensive as interest rates rise. He would prefer IHI-N if you like the healthcare space as he does.

DON'T BUY
DON'T BUY
September 18, 2018

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 18, 2018

They were working on some drug trials which didn't work as expected. Acqusitions didnt work out either The balance sheet is weaker than before. Some of their drugs will soon lose their patent.

HOLD
HOLD
September 12, 2018

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
September 12, 2018

Stock price has pushed up above the 200-day moving average. Longer term, this is an important space to be in. Good pipeline. Hold onto it at this point. Valuation is cheap. Trading at 9x earnings, expected 20% growth rate.

PAST TOP PICK
PAST TOP PICK
August 21, 2018

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
August 21, 2018

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

PARTIAL BUY
PARTIAL BUY
July 27, 2018

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
July 27, 2018

Nice chart. Really nice base in May/June around $79. If it can stay above $83, it’s looking pretty good. Potential to consolidate around $100, as an end of year target. If it drops another $8, start reducing. Take a small position only.

DON'T BUY
DON'T BUY
July 18, 2018

The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
July 18, 2018

The biotech sector is performing well. He would prefer to own the XBI-N ETF to get a basket and diversify risk.

PARTIAL BUY
PARTIAL BUY
July 9, 2018

It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.

Show full opinionHide full opinion

It is turning around. It got hammered and is showing some potential. It looks like it is breaking the downtrend. He is keeping a sharp eye on it. He is optimistic.

HOLD
HOLD
July 5, 2018

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

Show full opinionHide full opinion

Own widely. They had a number of missteps. They reduced their guidance. Great valuation. Some competitive threads coming in 2021-22. He would be cautious. (Analysts’ price target is $113.68)

WATCH
WATCH
June 20, 2018

He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
June 20, 2018

He has started watching this bio-tech company as their earnings have been improving. The technical chart looks bearish to him now. He will watch them. (Analysts’ price target is $114)

BUY
BUY
June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
June 14, 2018

This sector is fragmented and under valued. He likes it but has some short term issues that have hurt the stock. This is a negative momentum stock. Expects this to be higher in a year or 2. His favourite is Gilead in the sector.

TOP PICK
TOP PICK
May 30, 2018

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

Show full opinionHide full opinion

He's long owned this. They has a nasty surprise in 2017 when a drug failed to get approval, plus other issues. Currently it's selling at 9x earnings. Firmly believe their new products--with big upside--will carry this company higher. (Analysts' price target: $111.83)

PAST TOP PICK
PAST TOP PICK
May 28, 2018

(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.

Show full opinionHide full opinion

(A Top Pick May 28/17, Down 32%) It is considered best of class but stumbled and there is a negative sentiment to health care stocks. It is growing double digits but trading at a single digit multiple so he is just holding it for now.

DON'T BUY
DON'T BUY
May 28, 2018

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

Show full opinionHide full opinion

Not cheap, based on its historic valuation. Fundamentally, it's a good business, but its chart is unhealthy. Healthcare should be in any portfolio and this is a quality company. But Celgene ranks near the bottom of his medical/health stocks, 45 out of 49.

DON'T BUY
DON'T BUY
May 24, 2018

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

Show full opinionHide full opinion

Sold it a while ago. Looks cheap from a valuation standpoint trading at 9 times forward earning with a 19% growth rate. Investors are concerned about their cancer drugs patents expiring in a couple of years. Dark cloud surrounding the company.

DON'T BUY
DON'T BUY
May 9, 2018

They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.

Show full opinionHide full opinion

They completed a $5 billion buyback recently. They put up a beat on recent earnings, but there were concerns about future earnings. He does not like the space as there is a wall of sellers to overcome and bio-tech is running out of technical momentum. They have great forecasted cash flow, but watch out if they miss their guidance.

BUY
BUY
April 30, 2018

We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.

Show full opinionHide full opinion
Celgene Corp (CELG-Q)
April 30, 2018

We have some erosion here. You have to live with the overreaction. Around the $75 - $85 range there is probably a really good opportunity.

Showing 1 to 30 of 90 entries

Celgene Corp(CELG-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 4

Stockchase rating for Celgene Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Celgene Corp(CELG-Q) Frequently Asked Questions

What is Celgene Corp stock symbol?

Celgene Corp is a American stock, trading under the symbol CELG-Q on the NASDAQ (CELG). It is usually referred to as NASDAQ:CELG or CELG-Q

Is Celgene Corp a buy or a sell?

In the last year, 4 stock analysts published opinions about CELG-Q. 2 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Celgene Corp.

Is Celgene Corp a good investment or a top pick?

Celgene Corp was recommended as a Top Pick by Paul MacDonald on 2020-01-17. Read the latest stock experts ratings for Celgene Corp.

Why is Celgene Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Celgene Corp worth watching?

4 stock analysts on Stockchase covered Celgene Corp In the last year. It is a trending stock that is worth watching.

What is Celgene Corp stock price?

On 2020-01-03, Celgene Corp (CELG-Q) stock closed at a price of $108.24.